Pictor debuts new PictImager at ADLM 2026 to make targeted protein analysis more practical
Beta-site engagement begins as Pictor introduces an integrated 96-well workflow designed for scalable targeted protein analysis in research laboratories
27 Jul 2026
New PictImager® high-resolution protein analysis platform
Pictor Holdings Inc. will debut its next-generation high-resolution platform, PictImager®* at ADLM 2026 in Anaheim, California, at Booth 925. Designed to support scalable targeted protein analysis in research laboratories, the platform integrates Pictor's PictArray®, PictImager®, and simplified Pictorial© software into a streamlined workflow built around standard 96-well laboratory formats.
The introduction marks an important commercialization milestone for Pictor as the company begins beta-site engagement ahead of a planned full commercial launch later this year.
Targeted protein analysis is gaining momentum across translational research, biomarker discovery, and drug development. Adoption, however, remains constrained by workflow, specialized instrumentation, cost, and complexity. Pictor's platform is designed to address those barriers through compact instrumentation, targeted assay capability, and software-enabled analysis in a familiar 96-well format.
The new PictImager builds on earlier Pictor imaging systems that were developed primarily for research and technology development. The updated instrument incorporates enhanced design for improved usability and improved imaging capability, and a more robust architecture intended to support beta-site evaluation and broader commercial deployment. Pictor is also advancing its Pictorial© software to support automated image analysis, signal extraction, and workflow reporting across the integrated platform.
The integrated platform is designed to support research applications including biomarker research, translational research, immune profiling, oncology research, vaccine response, and longitudinal biomarker monitoring. It also supports multiple sample types, including serum, plasma, saliva, milk, cerebrospinal fluid, and nasal swabs.
Jamie Platt, PhD, CEO and co-founder, Pictor Holdings Inc., said, "Our goal has always been to make targeted protein analysis practical for more laboratories. The new PictImager® is an important milestone in that strategy, bringing improved imaging capability into a workflow designed for scalable targeted analysis. ADLM is the right setting to introduce the platform as we begin beta-site engagement and move toward broader commercial launch."
*The new PictImager® is for Research Use Only (RUO). Pictor is beginning beta-site engagement at ADLM; full commercial launch is planned for later in 2026.
Follow SelectScience throughout ADLM 2026 for exclusive interviews, daily round-up articles, Scientists' Choice Awards® coverage, and the latest news from the exhibition floor.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What is the PictImager platform and when will Pictor Holdings Inc. launch it commercially?
The PictImager® platform is Pictor Holdings Inc.’s next-generation high-resolution system for scalable targeted protein analysis in research laboratories. It integrates PictArray®, PictImager® and Pictorial© software into a streamlined 96-well workflow. Pictor is beginning beta-site engagement at ADLM 2026 in Anaheim, California, with a full commercial launch planned later in 2026.
How does the new PictImager address challenges in targeted protein analysis for translational research and drug development?
The new PictImager is designed to overcome barriers such as workflow complexity, specialized instrumentation, and cost in targeted protein analysis. It offers compact instrumentation, targeted assay capability, and software-enabled analysis in a standard 96-well format. Enhanced imaging, improved usability, and robust architecture support applications in translational research, biomarker discovery, and drug development.
Which research applications and sample types are supported by Pictor’s integrated PictImager platform?
Pictor’s integrated PictImager platform supports biomarker research, translational research, immune profiling, oncology research, vaccine response studies, and longitudinal biomarker monitoring. It is compatible with multiple sample types, including serum, plasma, saliva, milk, cerebrospinal fluid, and nasal swabs. The system is for Research Use Only (RUO). Pictor is beginning beta-site engagement at ADLM; full commercial launch is planned for later in 2026.